Replimune Group GAAP EPS of -$0.54 beats by $0.21
Replimune Q2 earnings beat estimates, with cash rising to $307.8M and R&D costs falling.
REPLIMUNE GROUP INC (REPL) is up +14.41% in the latest session. Our newswire has captured 3 stories on REPL across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100).
REPLIMUNE GROUP INC stock rose 6.37% to $13.36 in morning trading on Sept. 29, 2026, driven by a surge in investor interest amid multiple class action alerts and a recent capital-raising effort. The stock opened at $12.59 and climbed to an intraday high of $13.39 before settling near the high at $13.36. The move occurred as four separate class action notices were issued within 36 hours, each urging shareholders to consider legal action.
Four law firms issued class action alerts on behalf of Replimune Group, Inc. investors within a 36-hour period. The Portnoy Law Firm, Bronstein, Gewirtz & Grossman LLC, the Law Offices of Frank R. Cruz, and Levi & Korsinsky each announced separate lawsuits alleging investor harm and urging shareholders to evaluate their options. These alerts typically increase short-term trading activity as investors assess their legal exposure and potential for recovery. The Portnoy Law Firm set a lead plaintiff deadline of October 5, 2026, while others referenced similar claims. The timing of these alerts coincided with a broader period of market volatility and increased attention to the company's capital-raising moves.
The stock traded on a volume of 1.1 million shares, or 0.2 times the 3-month daily average, indicating elevated but not extreme liquidity. The price trend over the last 8 sessions showed a decline of 5.2% from $13.17 to $12.49, making the current rise notable against a recent downward trend. The stock closed at $13.36, just below its 52-week high of $16.33 and well above its 52-week low of $1.50. On the same day, the stock also printed one fresh 52-week low and 17 fresh 52-week highs, reflecting mixed retail and institutional sentiment. Recent insider transactions included five sales totaling $1.0 million, with the most recent occurring on August 19. The CEO and CFO both sold shares in early August.
Investors should monitor the lead plaintiff deadline of October 5, 2026, and any developments in the class action lawsuits. Additionally, coverage breadth and further capital-raising activity will be key indicators of the company’s near-term direction.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Replimune Q2 earnings beat estimates, with cash rising to $307.8M and R&D costs falling.
Filed: 2026-10-28 AccNo: 0001104659-26-119354 Size: 272 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
REPLIMUNE GROUP INC (REPL) is up +14.41% in the latest session. Our newswire has captured 3 stories on REPL across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100). The most recent driver: "Replimune Group GAAP EPS of -$0.54 beats by $0.21" (Seeking Alpha).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of REPL coverage reads 55/100 over 3 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on REPL: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier REPL move explainers: 2026-09-29 · 2026-09-11 · 2026-09-10